Natera shares surged to an all-time high Friday after the genetic testing company reported second-quarter results ahead of Wall Street expectations and raised its full-year revenue outlook, helped by strong oncology demand and continued momentum in Women's Health and Organ Health. Revenue rose 37.7% from a year earlier to $752.8 million, above the $660.7 million analyst estimate, while the company posted a loss of 47 cents per share versus expectations for a 51-cent loss. Natera processed about 1.04 million tests, up from roughly 853,100 a year earlier, and gross margin expanded to 64.5% as higher volumes and lower testing costs improved profitability. The company raised fiscal 2026 revenue guidance to $2.85 billion to $2.91 billion from $2.74 billion to $2.82 billion, above the $2.80 billion consensus estimate. The rally left the stock up 40.6% since the start of the year from around $228, after a low closing price of $182.65 in late March, and pushed co-founder Rabinowitz's billionaire fortune higher; he also held roughly 19.4% of genome firm MyOme on a fully diluted basis as of March 31.